Dx IPO Window Widens in 2021 as COVID-19 Testing Provides Jumping Off Point
Sustained investor interest in the diagnostics industry in light of the continuing COVID-19 pandemic drove initial public offerings in the Dx space in 2021, leading to more than three times as many IPOs in the space last year as in 2020.
Dx IPO Window Widens in 2021 as COVID-19 Testing Provides Jumping Off Point
Published in 360Dx
Author: Kelsy Ketchum and Craig Steger
Abstract:
Sustained investor interest in the diagnostics industry in light of the continuing COVID-19 pandemic drove initial public offerings in the Dx space in 2021, leading to more than three times as many IPOs in the space last year as in 2020.
Resources
Outcome Capital Congratulates Elios Vision on the Acquisition by Bausch + Lomb
Outcome’s strategic advisory and investment banking played a critical role in the inception, growth and success of ELIOS Vision
DownloadResources
Outcome Capital Life Science Market Pulse, December 2024
Outcome Capital Life Science Market Pulse December 2024 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Business Continuity Plan | Privacy Policy | Regulation Best Interest
